Skip to main content

Amneal Pharmaceuticals, Inc.

corporate_fare Company Profile

Amneal Pharmaceuticals, Inc.

AMRX·NASDAQ·Life Sciences·CIK 0001723128

Amneal Pharmaceuticals, Inc. is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. The company operates through three segments. Its Affordable Medicines segment includes retail generics, injectables, and biosimilars. The Specialty segment offers a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through its AvKARE segment, Amneal Pharmaceuticals is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. The company operates principally in the United States, India, and Ireland. Amneal Pharmaceuticals is a holding company. Immediately prior to a reorganization on November 7, 2023, the company held 50.4% of the common units of Amneal Pharmaceuticals, LLC, while the Amneal Group held the remaining 49.6%. On November 7, 2023, the company reorganized its corporate structure, converting to a traditional C-corporation structure. Effective with this reorganization, Amneal Pharmaceuticals holds 100% of the Amneal Common Units and continues to consolidate the financial statements of Amneal Pharmaceuticals, LLC and its subsidiaries. Prior to March 2023, the company had a minority economic interest in Amneal Pharmaceuticals, LLC but was its sole managing member, controlling its business decisions and management.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 40 items for AMRX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 9 rated 8 or above. Recent SEC coverage for AMRX spans 10-Q, 8-K/A, SCHEDULE 13D/A, 8-K.

Recent high-impact activity:

  • European Commission Approves Amneal's XOLAIR Biosimilar Adcomfo
  • Amneal 10-Q: Q3 Revenue Up 10% to $863M, but Kashiv Deal Drives $21.7M Quarterly Loss
  • Amneal Posts 6-Cent Loss Per Share in Third Quarter
  • Amneal Lifts 2026 Guidance as Q3 Revenue Climbs 10% to $863M
  • Amneal 8-K/A Reveals Kashiv Going-Concern Doubt and Restatement in Deal Financials

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.02B
Net Income
$72.06M
Diluted EPS
$0.22
Op. Cash Flow
$339.99M
Free Cash Flow
$269.93M
Gross Profit
$1.11B
Operating Income
$394.1M
Cash & Equivalents
$282.03M
Total Debt
$2.57B
Debt / Equity
-36.33×
Net Margin
2.4%
Shares Outstanding
313.37M sh
Source: 10-K · filed 2026-02-27 · accession 0001723128-26-000011

Short Interest & Short Volume

2.79 days to cover

FINRA reported short interest of 11,389,253 shares in AMRX as of the October 30, 2026 settlement, a 19.0% decrease from the prior period — about 2.8 days to cover at its recent average daily volume. On November 20, 2026, 74.1% of AMRX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)11,389,253 shares as of October 30, 2026
Change vs prior period▼ 19.0%
Days to cover2.79 at avg daily volume of 4,086,908
Daily short volume (FINRA facilities)74.1% of 543,727 shares on November 20, 2026
5-day average short volume58.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for AMRX, detected from its recent SEC filings.

1 shelf registration

28.9M Shares Registered for Resale · No Proceeds to Company

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$21.78 +3.15% today
52-week range · as of 2026-11-09 $11.29 – $21.78
Market cap
$7.36B
Volume
1.7M (0.4× avg)
3-mo avg 3.7M
Live data · 2026-11-21 04:25 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed AMRX - Latest Insights

AMRX
Nov 17, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $21.12
Real-time Price: $21.78 info
Change: +$0.6646 (+3%) info
Market Cap: $7.358B info
AMRX
Nov 09, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.28
Real-time Price: $21.78 info
Change: +$0.5046 (+2%) info
Market Cap: $7.358B info
AMRX
Nov 03, 2026, 6:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.23
Real-time Price: $21.78 info
Change: +$1.56 (+8%) info
Market Cap: $7.358B info
AMRX
Nov 03, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $20.20
Real-time Price: $21.78 info
Change: +$1.58 (+8%) info
Market Cap: $7.358B info
AMRX
Oct 23, 2026, 4:05 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $20.38
Real-time Price: $21.78 info
Change: +$1.40 (+7%) info
Market Cap: $7.358B info
AMRX
Sep 18, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $18.71
Real-time Price: $21.78 info
Change: +$3.07 (+16%) info
Market Cap: $7.358B info
AMRX
Aug 12, 2026, 6:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $17.33
Real-time Price: $21.78 info
Change: +$4.46 (+26%) info
Market Cap: $7.358B info
AMRX
Aug 12, 2026, 6:04 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $17.33
Real-time Price: $21.78 info
Change: +$4.46 (+26%) info
Market Cap: $7.358B info
AMRX
Aug 10, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.12
Real-time Price: $21.78 info
Change: +$3.67 (+20%) info
Market Cap: $7.358B info
AMRX
Aug 06, 2026, 5:19 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $18.38
Real-time Price: $21.78 info
Change: +$3.40 (+19%) info
Market Cap: $7.358B info
AMRX
Aug 03, 2026, 4:28 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $18.85
Real-time Price: $21.78 info
Change: +$2.93 (+16%) info
Market Cap: $7.358B info
AMRX
Jul 31, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.32
Real-time Price: $21.78 info
Change: +$3.46 (+19%) info
Market Cap: $7.358B info
AMRX
Jul 30, 2026, 6:15 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $21.00
Real-time Price: $21.78 info
Change: +$0.7846 (+4%) info
Market Cap: $7.358B info
AMRX
Jul 30, 2026, 6:02 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.60
Real-time Price: $21.78 info
Change: +$1.18 (+6%) info
Market Cap: $7.358B info
AMRX
Jul 17, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.03
Real-time Price: $21.78 info
Change: +$3.75 (+21%) info
Market Cap: $7.358B info
AMRX
Jun 29, 2026, 6:02 AM EDT
Filing Type: DEFM14A
Importance Score:
8
Price at Filing: $17.24
Real-time Price: $21.78 info
Change: +$4.54 (+26%) info
Market Cap: $7.358B info
AMRX
Jun 29, 2026, 3:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $16.83
Real-time Price: $21.78 info
Change: +$4.95 (+29%) info
Market Cap: $7.358B info
AMRX
Jun 18, 2026, 5:00 PM EDT
Filing Type: PREM14A
Importance Score:
8
Price at Filing: $16.21
Real-time Price: $21.78 info
Change: +$5.57 (+34%) info
Market Cap: $7.358B info
AMRX
Jun 17, 2026, 6:00 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $16.25
Real-time Price: $21.78 info
Change: +$5.53 (+34%) info
Market Cap: $7.358B info
AMRX
Jun 05, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $13.83
Real-time Price: $21.78 info
Change: +$7.95 (+58%) info
Market Cap: $7.358B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets